
|Videos|May 18, 2023
EMERALD Trial of Elacestrant in ER+, HER2- Advanced Breast Cancer: Efficacy and Safety Data
Expert oncologist Virginia Kaklamani, MD, DSc, joins the Oncology Brothers in highlighting the efficacy and safety data from the EMERALD trial and identifying appropriate use of elacestrant in patients with ER+, HER2- advanced breast cancer.
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves Subcutaneous Amivantamab for EGFR-Mutated NSCLC Indications
2
Enfortumab Vedotin Plus Pembrolizumab Improves Survival in MIBC
3
FDA Grants Regular Approval to Rucaparib for BRCA-Mutated mCRPC
4
Long-Term ECHO Data Support Concurrent Acalabrutinib/BR in MCL
5







































